Therapeutic impact of eicosapentaenoic acid on ischemic brain damage following transient focal cerebral ischemia in rats

Brain Res. 2013 Jun 26:1519:95-104. doi: 10.1016/j.brainres.2013.04.046. Epub 2013 May 2.

Abstract

Long-chain n-3 polyunsaturated fatty acids, such as eicosapentaenoic acid (EPA), have been shown to reduce ischemic neuronal injury. We investigated the effects of ethyl-EPA (EPA-E) on ischemic brain damage using a rat transient focal cerebral ischemia model. Male Sprague-Dawley rats (n=105) were subjected to 90 min of focal cerebral ischemia. EPA-E (100mg/kg/day) or vehicle was administered once a day for 3, 5 or 7 days prior to ischemia. Different withdrawal intervals of 3, 5, and 7 days prior to ischemia following 7-day pretreatment with EPA-E or vehicle were also examined. In addition, post-ischemic administration of EPA-E was investigated. Pretreatment with EPA-E for 7 and 5 days, but not 3 days, showed significant infarct volume reduction and neurological improvements when compared with vehicle pretreatment. In addition, withdrawal of EPA-E administration for 3 days, but not 5 and 7 days, also demonstrated significant infarct volume reduction and neurological improvements when compared with vehicle treatment. Post-ischemic treatment of EPA-E did not show any neuroprotection. Immunohistochemistry revealed that 7-day pretreatment with EPA-E significantly reduced cortical expression of 8-hydroxydeoxyguanosine (maker for oxidative DNA damage), 4-hydroxy-2-nonenal (maker for lipid peroxidation), phosphorylated adducin (marker for Rho-kinase activation) and von Willebrand factor (endothelial marker) when compared with vehicle pretreatment. In addition, phosphorylated adducin expression co-localized with von Willebrand factor immunoreactivity. The present study established the neuroprotective effect of EPA-E on ischemic brain damage following transient focal cerebral ischemia in rats, which may be involved in the suppression of oxidative stress and endothelial Rho-kinase activation.

MeSH terms

  • 8-Hydroxy-2'-Deoxyguanosine
  • Aldehydes / metabolism
  • Analysis of Variance
  • Animals
  • Brain Infarction / etiology
  • Brain Infarction / prevention & control
  • Brain Injuries / drug therapy*
  • Brain Injuries / etiology*
  • Deoxyguanosine / analogs & derivatives
  • Deoxyguanosine / metabolism
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Eicosapentaenoic Acid / therapeutic use*
  • Ischemic Attack, Transient / complications*
  • Magnetic Resonance Imaging
  • Male
  • Neurologic Examination
  • Neuroprotective Agents / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Time Factors
  • von Willebrand Factor / metabolism

Substances

  • Aldehydes
  • Neuroprotective Agents
  • von Willebrand Factor
  • 8-Hydroxy-2'-Deoxyguanosine
  • Eicosapentaenoic Acid
  • Deoxyguanosine
  • 4-hydroxy-2-nonenal